Our Update on COVID-19
March 23, 2020

At Leadiant Biosciences, Inc., we are closely monitoring the COVID-19 pandemic and its effect on the rare disease patient communities that we serve. For the safety of patients and families, healthcare professionals and our employees, we are following the Center for Disease Control and Prevention’s recommendation for “social distancing” and will provide support to physicians, patients and partners virtually until at least June 15. We will continue to monitor and assess information to determine if virtual support will be necessary for a longer period. We will continue to partner with patient communities, physicians, and researchers worldwide to overcome challenges and be a resource of hope.

To Our Patients, Families and Communities

The safety and welfare of the patients, families and communities that we serve is always our number one priority, especially during this global pandemic. At this time, we expect no impact on the supply and distribution of our medicines. We are committed to open and frequent communications to address any questions that you may have. We will maintain consistent monitoring of this unprecedented situation, provide updates of any changes and remain available to you. Our patient and physician support services are still available, and we remain fully committed to all of our communities during this pandemic.

Patients who are currently prescribed a Leadiant medicine and have a question should speak to their healthcare professional. Please see below for contact information if you have any questions or need any additional information:

Thank you,
The Leadiant Team